The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 medicines recall for a specific batch of Ramipril 2.5 mg capsules manufactured by Crescent Pharma Limited. The recall follows identification of a potential packaging error at the manufacturing site that could affect patient safety.
Immediate Action Required for Healthcare Providers
Healthcare professionals should immediately check their stock for the affected batch of Ramipril 2.5 mg capsules. The MHRA has classified this as a Class 2 recall, indicating a moderate risk where the product may cause temporary or medically reversible adverse health consequences.
Crescent Pharma Limited initiated the precautionary recall after discovering the potential packaging error during routine quality control procedures. The company has not disclosed the specific nature of the packaging defect in the initial alert.
Patient Safety Measures and Next Steps
Patients currently taking the affected Ramipril batch should continue their medication and consult their healthcare provider or pharmacist for guidance. Abruptly stopping ACE inhibitors like Ramipril can lead to rebound hypertension, according to NICE guidelines on hypertension management.
The recall specifically targets products distributed through UK pharmaceutical supply chains. Healthcare providers are advised to quarantine any remaining stock and contact their supplier for return instructions. More detailed safety information related to pharmacy and prescribing practices continues to be updated as investigations proceed.
Regulatory Response and Industry Impact
This recall highlights ongoing challenges in pharmaceutical quality control systems. The WHO’s Good Manufacturing Practice guidelines emphasize the critical importance of packaging integrity in maintaining drug safety and efficacy.
UK health authorities continue monitoring the situation closely. The MHRA’s rapid response demonstrates the effectiveness of post-market surveillance systems designed to protect patient welfare. Similar quality control measures have been implemented across health policy frameworks in other countries following comparable incidents.
Class 2 medicine recalls indicate products that may cause temporary or medically reversible adverse health consequences, requiring immediate healthcare provider action
— UK Medicines and Healthcare products Regulatory Agency (MHRA, 2026)
Key takeaways
- Crescent Pharma recalls specific batch of Ramipril 2.5 mg capsules due to packaging error
- Class 2 recall classification indicates moderate risk requiring immediate stock checks
- Patients should continue medication while seeking healthcare provider guidance
- Healthcare providers must quarantine affected stock and contact suppliers
Frequently asked questions
Should patients stop taking the recalled Ramipril immediately?
No, patients should continue taking their medication and consult their healthcare provider. Suddenly stopping ACE inhibitors can cause dangerous blood pressure spikes.
How can healthcare providers identify the affected batch?
The MHRA alert contains specific batch identification numbers that must be checked against current pharmacy stock immediately.
What does a Class 2 medicine recall mean?
Class 2 recalls indicate moderate risk where the product may cause temporary or medically reversible health consequences, requiring prompt but not emergency action.
Healthcare systems continue strengthening quality assurance protocols to prevent similar packaging errors. The swift identification and recall demonstrate effective collaboration between manufacturers, regulators, and healthcare providers in maintaining medication safety standards.
Source: Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 2.5 mg Capsules, EL(26)A/25
Was this article helpful?
Related Coverage
